CM
AVDL

Castleark Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Castleark Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-596,651
Closed -$10.2M – 356
2014
Q4 		$10.2M Buy
+596,651
New +$8.52M 0.26% 112
2013
Q4 		– Sell
-477,644
Closed -$6.83M – 318
2013
Q3 		$6.83M Buy
+477,644
New +$2.94M 0.19% 136

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Castleark Management's AVDL Position: Q1 2015 in Review

Castleark Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2015, closing a stake of 596,651 shares — an estimated $10.2M sold.

Castleark Management first reported a position in AVDL in Q3 2013 and held it in 2 quarters. The position peaked at $10.2M in Q4 2014. 84 funds tracked by Wall St. Rank hold AVDL as of Q1 2015.

  • Castleark Management reported no remaining Avadel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Castleark Management sold 596,651 Avadel Pharmaceuticals shares in Q1 2015, an estimated $10.2M.
  • Castleark Management first reported a position in Avadel Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Castleark Management's Avadel Pharmaceuticals position peaked at $10.2M in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2015.

Based on Castleark Management's 13F filing for Q1 2015, filed 15 May 2015.